Marc Van de Vijver
Overview
Explore the profile of Marc Van de Vijver including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
6158
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hung T, Wang Y, Lin M, Koegel A, Kotake Y, Grant G, et al.
Nat Genet
. 2011 Jun;
43(7):621-9.
PMID: 21642992
Transcription of long noncoding RNAs (lncRNAs) within gene regulatory elements can modulate gene activity in response to external stimuli, but the scope and functions of such activity are not known....
12.
Kok M, Linn S, Van de Vijver M
Cancer Treat Res
. 2011 Apr;
147:1-18.
PMID: 21461831
No abstract available.
13.
Artez A, Bernabe R, Eerola I, Hemsley F, Jennings J, Kerr D, et al.
Nature
. 2010 Apr;
464(7291):993-8.
PMID: 20393554
The International Cancer Genome Consortium (ICGC) was launched to coordinate large-scale cancer genome studies in tumours from 50 different cancer types and/or subtypes that are of clinical and societal importance...
14.
Broeks A, Braaf L, Wessels L, Van de Vijver M, De Bruin M, Stovall M, et al.
Int J Radiat Oncol Biol Phys
. 2010 Feb;
76(2):540-7.
PMID: 20117289
Purpose: Women who received irradiation for Hodgkin's lymphoma have a strong increased risk for developing breast cancer. Approximately 90% of the breast cancers in these patients can be attributed to...
15.
Bilous M, Osamura R, Ruschoff J, Van de Vijver M, Hanna W, Penault-Llorca F, et al.
Hum Pathol
. 2009 Nov;
41(2):304-5.
PMID: 19914678
No abstract available.
16.
Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura R, Ruschoff J, et al.
Am J Clin Pathol
. 2009 Sep;
132(4):539-48.
PMID: 19762531
Patients with human epidermal growth factor receptor-2 (HER2)+ breast cancer are eligible for trastuzumab treatment; therefore, accurate assessment of HER2 status is essential. Until recently, only 2 methods were validated...
17.
de Ronde J, Hannemann J, Halfwerk H, Mulder L, Straver M, Vrancken Peeters M, et al.
Breast Cancer Res Treat
. 2009 Aug;
119(1):119-26.
PMID: 19669409
ER, PR and HER2 status in breast cancer are important markers for the selection of drug therapy. By immunohistochemistry (IHC), three major breast cancer subtypes can be distinguished: Triple negative...
18.
Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R, et al.
Arch Pathol Lab Med
. 2009 Jun;
131(1):18-43.
PMID: 19548375
Purpose: To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2(HER2) testing in invasive breast cancer and its utility as a predictive marker. Methods: The...
19.
van Nes J, Putter H, Julien J, Tubiana-Hulin M, Van de Vijver M, Bogaerts J, et al.
Breast Cancer Res Treat
. 2008 May;
115(1):101-13.
PMID: 18484198
Introduction: The Preoperative Chemotherapy in Primary Operable Breast Cancer (POCOB) study was designed to compare preoperative with postoperative chemotherapy in patients with early breast cancer concerning breast conserving therapy (BCT)...
20.
Jongsma J, van Montfort E, Vooijs M, Zevenhoven J, Krimpenfort P, van der Valk M, et al.
Cancer Cell
. 2008 Mar;
13(3):261-71.
PMID: 18328429
Malignant mesothelioma is a devastating disease that has been associated with loss of Neurofibromatosis type 2 (NF2) and genetic lesions affecting RB and P53 pathways. We introduced similar lesions in...